A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥4 Years to <17 Years of Age With Partial Onset Seizures
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB
- 28 Aug 2019 Primary endpoint (Change in Partial Onset Seizure (POS) Frequency Per 28 Days From Baseline to the Maintenance Period) has been met as published in the Neurology
- 28 Aug 2019 Results assessing efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal partial seizures published in the Neurology
- 27 Apr 2018 Results of a post-hoc analysis, presented at the 70th Annual Meeting of the American Academy of Neurology.